Our team works hard to drive our innovative pipeline programs into and through clinical development to assess the safety, tolerability, and immunogenicity of each candidate.
We are grateful for the many volunteers and medical experts who participate in our studies, without whom we could not reach our goal of better health for all.
Prophylactic Vaccine : 3-Antigen HBV Vaccine (Sci-B-Vac®)
Study PROTECT
Phase 3: A double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac® compared to Engerix-B® in adults ≥ 18 years old and the superiority of Sci-B-Vac® compared to Engerix-B® in ≥ 45 years old.
Status: Completed
Study CONSTANT
Phase 3: A double-blind randomized controlled trial to assess the lot-to-lot consistency of Sci-B-Vac® in adults
Status: Completed
Immunotherapeutic Candidate: VBI-2601
Phase 1b/2a: Ongoing study evaluating the safety, tolerability, and antiviral activity of VBI-2601 (BRII-179) as a component of a functional cure for chronic HBV infection, developed in partnership with Brii Biosciences.
Status: Active, Not Recruiting
Immunotherapeutic Candidate : VBI-1901
Phase 1/2a: Ongoing study evaluating the safety, tolerability, and optimal dose of VBI-1901 in subjects with recurrent GBM.
Status: Active, Not Recruiting
Prophylactic Candidate : VBI-1501
Phase 1: Study to compare the safety and effectiveness of four different doses of VBI’s CMV vaccine candidate in healthy adults.
Status: Completed
